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Objectives'. We tested how insulin-glucose infusion followed by 
multidose insulin treatment in diabetic patients with acute myo- 
cardial infarction affected mortality during the subsequent 12 
months of follow-up. 
Background. Despite significant improvements in acute coro- 
nary care, diabetic patients with acute myocardial infarction still 
have a high mortality rate. 
Methods. A total of 620 patients were studied: 306 randomized 
to treatment with insulin-glucose infusion followed by multidose 
subcutaneous insulin for >3 months and 314 to conventional 
therapy. 
Results. The two groups were well matched for baseline char- 
acteristics. Blood glucose decreased from 15.4 _+ 4.1 to 9.6 -+ 
3.3 mmol/liter (mean -+ SD) in the infusion group during the 1st 
24 h, and from 15.7 -+ 4.2 to 11.7 -+ 4.1 among control patients 
(p < 0.0001). After 1 year 57 subjects (18.6%) in the infusion 
group and 82 (26.1%) in the control group had died (relative 
mortality reduction 29%, p = 0.027). The mortality reduction was 
particularly evident in patients who had a low cardiovascular risk 
profile and no previous insulin treatment (3-month mortality rate 
6.5% in the infusion group vs. 13.5% in the control group [relative 
reduction 52%, p = 0.046]; 1-year mortality rate 8.6% in the 
infusion group vs. 18.0% in the control group [relative reduction 
52%, p = 0.020]). 
Conclusions. Insulin-glucose infusion followed by a multidose 
insulin regimen improved long-term prognosis in diabetic pa- 
tients with acute myocardial infarction. 
(J Am Coil Cardiol 1995;26:57-65) 
Patients with diabetes mellitus have a considerably higher 
short- and long-term mortality rate after myocardial infarction 
than do nondiabetic patients (1-7). This difference has re- 
mained espite the introduction of new therapeutic measures 
that have decreased overall morbidity and mortality after acute 
myocardial infarction (8-12). Because diabetes mellitus is 
rather common among patients with infarction, its relative 
impact on mortality in ischemic heart disease seems to be 
increasing (13,14). It has been suggested that diabetic patients 
have a more extensive and distal coronary artery, disease with 
preexisting cardiac dysfunction due to diabetic ardiomyopathy 
and autonomic mbalance (15-17). Such factors could explain 
the increased mortality in diabetic patients with acute myocar- 
dial infarction. In diabetes, fatty acid metabolism ispresumably 
increased, compromising lycolysis not only in ischemic but 
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also in nonischemic areas (18). Beta-adrenergic blocking 
agents reduce lipolysis and the amount of circulating free fatty 
acids. Subgroup analyses from postmyocardial nfarction stud- 
ies demonstrate hat beta-blockade seems to be of special 
benefit in diabetic patients (19,20). Another way to suppress 
free fatty acid oxidation is by the infusion of insulin-glucose 
(21). On the basis of a small study and the use of historical 
control subjects, Clark et al. (22) suggested that improved 
metabolic ontrol by means of intravenous insulin could re- 
duce the high initial complication rate and mortality among 
diabetic patients with acute myocardial infarction. Another 
similar study reached contradictory esults (23). Prospective 
studies designed and powered to demonstrate mortality reduc- 
tion by means of insulin-glucose infusion in diabetic patients 
with acute myocardial infarction have so far not been reported 
(24). 
The impairment of platelet and fibrinolytic function in 
patients with diabetes mellitus (25,26) also may contribute to 
the high rate of early recurrent infarction. Insulin treatment 
has recently been shown (25,27) to reduce thromboxane A 
production and to decrease plasma plasminogen activator 
inhibitor-I activity. These observations give further theoretic 
support to the hypothesis that insulin therapy in the immediate 
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Table 1. Protocol Used by the Coronary Care Unit Nurses for the Insulin-Glucose Infusions 
Infusion: 500 ml 5% glucose with 80 IU of soluble insulin (-1 IU/6 ml). 
Start with 30 ml/h. Check blood glucose after 1 h. Adjust infusion rate according to the protocol and aim for a blood 
glucose level of 7 to 10 retool/liter. Blood glucose should be checked after 1 h if infusion rate has been changed, 
otherwise very. 2h. If the initial decrease in blood glucose xceeds 30%, the infusion rate should be left 
unchanged if blood glucose is >11 mmol/liter and reduced by 6 ml/h if blood glucose is within the targeted range 
of 7 to 10.9 retool/liter. 
If blood glucose is stable and -<10.9 mmoLqiter after 10 eM, reduce infusion rate by 50% during night. 
Blood Glucose Level (mmol/liter) 
>15 mmol/liter: 
11 to 14.9 mmol/liter: 
7 to 10.9 mmol/liter: 
4 to 6.9 mmol/liter: 
<4 mmol/liter: 
Give 8 1U of insulin as an intravenous bolus injection and increase infusion rate by 6 ml/h. 
Increase infusion rate by 3 ml/h. 
Leave infusion rate unchanged. 
Decrease infusion rate by 6 ml,ql. 
Stop infusion for 15 rain. Then test blood glucose and continue testing every 15 min until 
blood glucose is ->7 mmol/liter. In the presence of symptoms of hypoglycemia, 
administer 20 ml of 30% glucose intravenously. The infusion is restarted with an 
infusion rate decreased by 6 ml/h when blood glucose is ->7 mmot/liter. 
peri-infarction period may improve the ischemic damage and 
prognosis. 
The DIGAMI study (Diabetes Mellitus Insulin-Glucose 
Infusion in Acute Myocardial Infarction) was initiated to test 
the hypothesis that rapid improvement of metabolic control in 
diabetic patients with acute myocardial infarction by means of 
insulin-glucose infusion decreases the high initial mortality 
rate and that continued good metabolic ontrol during the 
early postinfarction period improves the subsequent prognosis. 
Methods 
Definitions. Diabetes mellitus. Diabetes mellitus was con- 
sidered present if a patient had been given this diagnosis and 
was receiving treatment (diet, tablets or insulin). Patients with 
no previous diagnosis of diabetes mellitus but with a blood 
glucose level ->11 mmol/liter on admission were classified as 
having newly detected iabetes mellitus and were also in- 
cluded. The patients were classified as non-insulin-dependent 
or insulin-dependent by clinical history and according to the 
definitions of the National Diabetes Data Group (28). Thus, 
patients considered non-insulin dependent were usually >40 
years old at diagnosis, had not required insulin for 2 years after 
the diagnosis and were not prone to ketosis. 
Myocardial infarction. The diagnosis "definite myocardial 
infarction" required fulfillment of at least wo of the following 
criteria: 1) chest pain of at least 15 rain duration; 2) at least wo 
values of serum creatine kinase and serum creatine kinase B 
above the normal range (normal value +2 SD) 10 to 16 h after 
the onset of symptoms or at least wo serum lactic dehydroge- 
nase values +2 SD above the normal range 48 to 72 h after 
onset of symptoms, including an isoenzyme pattern typical of 
myocardial infarction; 3) development of new Q waves in at 
least 2 of the 12 standard ECG leads. The diagnosis "possible 
myocardial infarction" was made if typical chest pain was 
combined with only one serum creatine kinase or serum lactic 
dehydrogenase value above the normal range or if Q waves 
appeared in only 1 of the 12 standard ECG leads, or both. A 
reinfarction was defined as an event fulfilling the criteria given 
for a myocardial infarction but appearing >72 h after the index 
infarction. 
Study design. In the multicenter DIGAMI study all pa- 
tients admitted to the coronary care units of 19 Swedish 
hospitals (see Appendix) were considered for inclusion. Inclu- 
sion criteria were suspected acute myocardial infarction within 
the preceding 24 h combined with previously known diabetes 
mellitus and a blood glucose level > 11 mmol/liter or a blood 
glucose level >11 retool/liter even without known diabetes 
mellitus. The following exclusion criteria were applied: inabil- 
ity to participate for reasons of health (e.g., too sick to give 
informed consent or unable to manage multidose insulin 
treatment), refusal to participate, residence outside the hospi- 
tal catchment area, enrollment in other studies and previous 
participation in DIGAMI. Subjects without any exclusion 
criteria were randomized in blinded manner to one of two 
groups: insulin-glucose or control. In addition to standard 
coronary care unit therapy, patients in the insulin-glucose 
group received an insulin-glucose infusion according to a 
predefined protocol for ---24 h (Table 1), then subcutaneous 
insulin four times daily for ->3 months. Control patients were 
treated according to standard coronary care unit practice and 
did not receive insulin unless it was deemed clinically indi- 
cated. 
The patients were classified as being at high risk if they 
fulfilled two or more of the following criteria: age >70 years, 
history of previous myocardial infarction, history of congestive 
heart failure, current reatment with digitalis. Before random- 
ization the patients were stratified into one of four groups 
according to risk classification (high; low) and to previous 
antidiabetic treatment (insulin; no insulin). Predefined strata 
were: 1) no insulin, low risk; 2) no insulin, high risk; 3) insulin, 
low risk and 4) insulin, high risk. 
The DIGAMI protocol was approved by the ethical corn- 
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mittees at the Karolinska Institute and the Universities of 
Gothenburg, LinkOping, Lund and Uppsala, Sweden. 
The insulin-glucose infusion was started by the nurse in 
charge of the coronary care unit as soon as possible after the 
patient's arrival. Samples for determination f blood glucose 
were drawn from an intravenous cannula at time intervals 
outlined in the protocol (Table 1). The accuracy and feasibili~ 
of the method used have been previously described (29). The 
infusion was continued until stable normoglycemia was at- 
tained and always for ->24 h. Subcutaneous administration f 
insulin was instituted immediately after cessation of the infu- 
sion, according to a multidose regimen, with the aim of 
maintaining stable normoglycemia. It consisted of soluble 
insulin administered through an insulin pen three times daily 
before meals combined with medium-long-acting i sulin in the 
evening (Isuhuman Rapid, Isuhuman Basal; Optipen, Hocchst 
AG, Sweden). Subcutaneous insulin treatment was withdrawn 
if serious hypoglycemic events occurred espite repeated ose 
adjustments. In patients who proved unable to manage the 
insulin treatment because of a physical or psychiatric handicap, 
attempts were made to obtain the assistance ofa district nurse 
or a relative before treatment was stopped. 
Serum potassium (normal range 3.5 to 5.0 mmol/liter) was 
measured immediately before the insulin-glucose infusion and 
then after 6, 12 and 24 h. Serum potassium was checked 
immediately in patients who developed any kind of clinically 
significant arrhythmia. 
Concomitant therapy. The patients received treatment 
other than glucose-insulin i fusion according to predefined 
guidelines. If there were no contraindications, thrombolytic 
treatment was administrated to patients with onset of symp- 
toms within 6 h and an electrocardiogram (ECG) with ST 
segment elevation ->1 mm in the limb leads or ->2 mm in the 
chest leads or with left bundle branch block. Streptokinase 
(Behring, Germany), 1.5 × 106 IU, was infused over 60 min. 
Unless contraindicated, intravenous beta-blockade was initi- 
ated by repeated injections of metoprolol (Seloken, ASTRA, 
Sweden; up to 3 × 5 mg over 60 min) immediately after 
admission. This treatment was followed by administration f 
oral metoprolol, up to 200 mg daily, according to a previously 
described protocol, with the aim of obtaining optimal beta- 
blockade as early as possible (9). 
Statistics. The primary aim of this study was to evaluate 
whether the insulin-glucose infusion followed by multidose 
insulin for 3 months reduced mortality at 3 months in diabetic 
patients with acute myocardial infarction. An earlier etrospec- 
tive analysis of postinfarction patients with diabetes discharged 
from a Swedish ospital (4) revealed a3-month mortality rate 
of 35%. With some variations, other studies (22,23,30) usually 
reported even higher mortality rates. We hypothesized that 
insulin-glucose infusion followed by multidose subcutaneous 
insulin for 3 months would reduce the mortality rate by 30%, 
from a 35% mortality rate in the control group. On the basis of 
this assumption, -600 patients had to be randomized to 
demonstrate the expected mortality reduction with a 5% 
significance l vel and a power of 80%. 
Eligible [ -~  
ExcludedRandomized f ~ ~  ~ Incapable 280 (45%) 
Unwilling 238 (38%) 
/ N~ Outside area 40 (7%) 
In other studies 34 (5%) 
Already inDIGAMI 28 (5%) 
Excluded patients 
~ Age (years+SD) 71+_11 
Control group Infusion group Male (no; %) 355 ;57 
Female (no; %) 265 ;43 
Figure l. Schematic presentation f logged, excluded and included 
patients inthe present Diabetes Mellitus Insulin-Glucose Infusion in 
Acute Myocardial Infarction (DIGAMI) study. 
Standard statistical methods were used. The significance of 
the differences between the two groups were tested by Student 
t test and Fisher exact test. Differences within groups were 
tested by a paired test. For survival data the log-rank test was 
used. The effect and its confidence interval were estimated by 
the relative hazards rate in a Cox analysis (31). Cumulative 
mortality curves were estimated by the Kaplan-Meier method. 
To adjust simultaneously for other factors the Cox model was 
used. A two-tailed p value < 0.05 was considered statistically 
significant. 
Results 
Between January 1, 1990 and December 18, 1993 a total of 
1,240 patients fulfilled the inclusion criteria. Fifty percent (n = 
620) were excluded, the vast majority because of inability or 
unwillingness toparticipate (Fig. 1). Compared with patients in 
the study, excluded subjects were somewhat older and more of 
them were women. 
Of the 620 included patients, 306 were randomly allocated 
to insulin-glucose infusion followed by multidose subcutaneous 
insulin treatment (infusion group) and 314 to the control 
group. The mean time from onset of symptoms to randomiza- 
tion was 13 +_ 7 h. The two groups were well matched in 
baseline characteristics (Table 2). More than 80% of the 
patients were characterized clinically as non-insulin depen- 
dent; 13% were not previously known to have diabetes melli- 
tus. At hospital admission a relatively large proportion were 
already being treated for cardiovascular disorders (Table 2). 
The body mass index of 27 in both groups indicated that the 
patients were slightly overweight. 
At hospital admission 226 patients (74%) in the infusion 
group and 232 (74%) in the control group showed ECG signs 
of ongoing myocardial ischemia, and during the hospital stay, 
definite myocardial infarction developed in270 patients (88%) 
in the infusion group and 264 (84%) in the control group (p = 
NS). The respective proportion of patients with possible 
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Table 2. Prehospital Characteristics* 
Control Group Infusion Group 
(n -  314) (n 306) 
No. (:f No. cf 
Age (yr) 68 + 9 67 + 9 
Male 197 63% 191 62~- 
Female 117 37% 115 38% 
BMI (kg/m 2) 27 + 4 27 _+ 4 
Previous disease 
Myocardial infarction 117 37% 121 4(15; 
Angina pectoris 164 52% 176 58% 
Hypertension 154 49 % 143 475~ 
Congestive heart failure 71J 22% 69 23';~ 
Type of diabetes mellitus 
Non-insulin dependent 265 84% 251 g2~::2 
Insulin dependent 49 16¢5 55 18% 
Previously unknown 47 15 % 31 10(:; ~ 
Duration (yr) llJ _+ 10 10 + 10 
Antidiabetic treatment 
None 47 15% 31 10% 
Diet 39 12% 33 1 l~i 
Tablets 115 37% 140 46% 
Insulin 113 36% 1112 33 c)~ 
Other treatment 
Beta-blockers 112 36% 121 40% 
Aspirin 111 35% 93 30% 
Nitrates 8(1 25% 81 26% 
ACE inhibitors 54 17% 45 14% 
Digoxin 56 18% 49 16% 
Smoker 73 23% 70 23% 
*There were no significant differences between groups. Data are expressed 
as number or percent of patients or mean value + SD. ACE angiotensin- 
converting enzyme: BMI - body mass index. 
myocardial infarction was 9 (3%) and 23 (7%) (p = NS). Only 
<2% of patients lacked evidence of ischemic heart disease. 
The proportion of patients with anterior wall infarction was 
50% in both groups. 
In-hospital metabolic variables are given in Table 3. During 
the 1st 24 h blood glucose decreased significantly in both 
groups, with a greater decrease in the infusion group (5.8 _+ 4.9 
vs. 4.0 _+ 3.9 mmol/liter, p < 0.0001). In the insulin-glucose 
group the blood glucose decreased relatively rapidly during the 
first hours, with a nadir of 7.1 _ 3.1 mmol/liter 6 h after the 
start of the infusion. During the 1st 24 h hypoglycemia 
developed in 46 patients (15%) in the infusion group com- 
pared with none in the control group (p < 0.0001). During the 
hospital stay 172 control patients (55%) received an extra 
bolus of soluble insulin at least once. 
At hospital discharge 87% of patients in the insulin-glucose 
group were receiving insulin treatment, compared with 43% in 
the control group (p < 0.0001). After the 3-month visit these 
proportions were 80% and 45%, respectively (p < 0.0001); 
after the 1-year visit (n = 376) they were 72% and 49~, 
respectively (p < 0.0001). 
At the 3-month follow-up study the fasting blood glucose 
level was 8.5 _+ 3.1 mmol/liter in the infusion group and 9.0 _+ 
Table 3. Biochemical Variables During the In-Hospital Period 
Control Infusion 
Group Group p 
(n 314) (n 306) Value 
HbA1, at randomization (%)* 8.0 ± 2.0 8.2 _+ 1.9 NS 
Blood glucose (retool/liter) 
At randomization 15.7 _+ 4.2 15.4 + 4.1 NS 
24 h after randomization ! 1.7 + 4.1 9.6 _+ 3.3 < 0.0001 
At hospital discharge 9.0 + 3.0 8.2 -+ 3.1 < 0.01 
Serum potassium (retool/liter) 
At randomization 4.3 + 0.5 4.3 _+ 0.5 NS 
24 h after randomization 4.2 _+ 0.5 4.0 _+ 0.4 < 0.001 
Hypoglycemia during infusion 0 46 [15] < 0.0001 
(no. [c~] of patients) 
Serum lactate dehydrogenase 10.1 _+ 9.5 9.3 _+ 8.8 NS 
48 h after onset of symptoms 
(p, kat/liter)+ 
~n = 266 and 257 in the infusion and control groups, respectively. ?n = 210 
and 201 in the infusion and control groups, respectively. Data are presented as 
mean value + SD, unless otherwise indicated. 
3.2 mmol/liter in the control group (p = NS). At that time 
glycosylated hemoglobin HbAlc (n = 459) was 7.0 _+ 1.6% in 
the infusion group and 7.5 _+ 1.8% in the control group (p < 
0.01). The HbAtc level decreased significantly in both groups 
during the follow-up period but significantly more in the 
infusion group (1.1 _+ 1.6% vs. 0.4 + 1.5% after 3 months [p < 
0.0001] and 0.9 _+ 1.9% vs. 0.35 _+ 1.8% after 1 year [p < 0.05]). 
Fasting blood glucose 1 year after andomization did not differ 
between the two groups. 
During the in-hospital period almost 50% of the patients 
were given thrombolysis and intravenous nitroglycerin and 
17% were fully heparinized. At the time of hospital discharge 
80% of the patients were receiving aspirin and 70% were 
receiving beta-blockers. Angiotensin-converting enzyme inhib- 
itors were given to 31% of patients. Except for antidiabetic 
treatment including insulin, there were no significant differ- 
ences in the in-hospital or follow-up treatment between the 
two groups. During the follow-up year 13 patients in each 
group underwent percutaneous transluminal coronary angio- 
plasty, and coronary artery bypass urgery was performed in30 
patients in the infusion group and in 29 in the control group. 
In-hospital morbidity. The hospital stay was 11.3 _+ 13.3 
days in the infusion group and 9.5 -+ 9.4 days in the control 
group (p = 0.043). During the hospital period the control 
group did not differ from the infusion group regarding rein- 
farction (4% vs. 5%), ventricular fibrillation (5% vs. 3%), high 
degree atrioventricular conduction disturbances (3% vs. 7%) 
or congestive heart failure (48% vs. 50%). 
Mortality. Mortality data are presented in Table 4. The 
mean follow-up time for all patients was 344 days (range 91 to 
365). The overall mortality rate was considerably ower than 
expected and was lower at each checkpoint in the infusion 
group than in the control group (Fig. 2). The 3-month mortal- 
i V rate was 12.4% in the infusion group versus 15.6% in the 
control group (p = NS); the corresponding data at i year were 
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Table 4. Mortality at Various Follow-Up Times 
Control Infusion Mortali), 
Total Group Group Reduction 
(n - 620) (n - 314) (n - 306) 
P 
Time No. % No. ~ No. % % Value 
In-hospital 63 10.2 35 11.1 28 9.1 18 NS 
3 months 87 14.0 49 15.6 38 12.4 21 NS 
1 year* 139 22.4 82 26.1 57 18.6 29 0.0273 
*See text for follow-up time. Log-rank test used. 
18.6% and 26.1% (p = 0.0273). The relative reduction in 
mortality was 29% by the crude method and 31% with the Cox 
model. The corresponding confidence interval was 4% to 51%. 
The mortality rates within the prestratified risk groups are 
presented inTable 5. In stratum 1, consisting of patients with 
a low cardiovascular risk profile and no previous insulin 
treatment, he mortality reduction was 52% after 3 months 
(p = 0.046). This difference persisted at 1 year, with a mortality 
rate of 8.6% in the infusion group and 18.0% in the control 
group (relative risk reduction 52%, p = 0.020). 




20 ~ ~ - -  Infusion 
tO 
.028 
05 [~ Effect: Crude 29%; Cox 31% 
I 95% Conf. Int. 4-51% 
0 I I I I I I I I I 
0 50 100 150 200 250 300 350 400 
Days 
Patients at risk 
Control 314 265 230 211 193 
Active 306 268 239 223 199 
Figure 2. Actuarial mortality curves in the patients receiving insulin- 
glucose infusion and in the control group of the present Diabetes 
Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 
(DIGAMI) study during 1 year of follow-up. Numbers below graph = 
number of patients at different times of observation. Active = patients 
receiving infusion; Conf. Int. = confidence interval. 
Discuss ion 
The main conclusion from this study is that the long-term 
overall mortality in diabetic patients with acute myocardial 
infarction could be further educed by the administration of 
insulin-glucose infusion followed by multidose subcutaneous 
insulin. The mortality rate was reduced by 30% after 1 year. 
Patients without previous insulin treatment and with a rela- 
tively low risk profile benefited the most. 
Mortality in diabetic patients with myocardial infarction. 
The mortality rate in the present study is lower than that 
previously reported (4,30). This finding is especially encourag- 
ing because the patients' prehospital characteristics show that 
many were at high risk. Almost 40% had a previous infarction 
and >50% had angina pectoris. Approximately 20% were 
receiving therapy for congestive heart failure. In-hospital treat- 
ment was active and half of the patients received thrombolytic 
therapy. In the International Study of Infarct Survival (ISIS) II 
trial (32), diabetic patients benefited more than nondiabetic 
patients from streptokinase. Other studies (7,33,34) have also 
shown at least as good an effect of thrombolytic therapy among 
diabetic as among nondiabetic patients. A recent study (35) 
reported a 42% reduction in in-hospital mortality among 
diabetic patients after the introduction of thrombolytic ther- 
apy. 
The high proportion of patients given beta-blockers (70%) 
probably also contributed to the good prognosis in our study. 
We and others (19,20,36) have reported on the excellent 
secondary preventive ffect of beta-blockers in diabetic post- 
myocardial infarction patients. Traditionally, diabetic patients 
have been considered less suitable for beta-blockade because 
of fear of worsening of metabolic ontrol and of more severe 
hypoglycemic attacks with diminished hypoglycemic warning 
signs (37-42). However, these drawbacks have not been con- 
firmed with betal-selective blocking agents (40,41,43). 
Eighty percent of our patients were discharged on a regi- 
men of aspirin therapy. Thromboxane A production and 
platelet aggregability are increased in diabetic patients (25). 
Furthermore, such patients are thought to require larger doses 
of aspirin to inhibit platelet aggregation than those needed by 
nondiabetic patients (33). For example, in ISIS-II (32) there 
was no reduction in mortality among diabetic patients receiv- 
ing aspirin (160 mg daily) compared with a 20% reduction 
among nondiabetic patients. In the present study most patients 
received only 75 mg of aspirin daily but even so the mortality 
was low. According to Davi and co-workers (25), insulin 
treatment decreases thromboxane A production in patients 
with type II diabetes mellitus; however, this observation cannot 
explain the rather low mortality in our control group. 
Study limitations. It was not considered feasible or safe to 
design a nurse-based blinded protocol for administration f
insulin-glucose treatment in a multicenter trial. Great care was 
taken to keep the study blinded until the patients were 
allocated to the predefined strata, and, in fact, the two groups 
were well matched at randomization. If it had any effect, the 
lack of blinding may have blunted a possible beneficial out- 
come because of a carryover effect. Altogether 55% of the 
control patients received at least one extra bolus of insulin 
during the hospital stay and HbAlc decreased significantly 
among the control patients during follow-up, indicating im- 
proved metabolic ontrol. However, only a few of these 
patients were transferred to treatment with subcutaneous 
insulin at hospital discharge. Institution of insulin therapy may 
be paralleled by a general improvement in the care of the 
patient, contributing to the beneficial outcome. However, this 
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Table 5. Mortality in Prestratified Risk Groups 
Stratum 1 Stratum 2 Stratum 3 Stratum 4
Patient mortality 272 (44%)* 129 (21%)* 119 (19%)* 100 (16%)* 
3 month 9.9% 16.3% 12.6% 24.4% 
1 year 13.2c,~ 29.5 ~Jl 20.9% 41.0% 
Mortality by group+ 
Control group 
3 month 18 (13.5%) 10 (15.2%) 8 (12.3%) 13 (26.0%) 
1 year 24 (18.0%) 21 (31.8%) 14 (21.5%) 23 (46.0%) 
Insulin group 
3 month 9 (6.5%) I1 (17.5%) 7 (13.0%) 11 (22.0%) 
I year 12 (8.6%) 17 (27%) 10 (18.5%) 18 (36.0%) 
Mortality reduction 
3 month 52%:~ 11% 0% 15% 
1 year 52%:~ 15g'~ 14% 22% 
*Percent of total patients. +Number (%) of patients. :~p - (I.046, p - 0.020 log-rank test, Stratum 1 - no insulin, low 
risk: Stratum 2 no insulin, high risk; Stratum 3 = insulin, low risk; Stratum 4 insulin, high risk. 
should not be seen as a bias but rather as part of a compre- 
hensive care program for diabetic patients with myocardial 
infarction. Arguing against such an effect is that concomitant 
therapy including revascularization procedures did not differ 
between the two groups. 
The considerably lower than predicted overall mortality 
rate has already been emphasized. Therefore, the sample size 
turned out to be relatively small, a factor that explains the wide 
confidence intervals. Nevertheless, there was a consistent and 
continuous mortality, reduction, which became significant after 
i year of follow-up. Although the study group was small in the 
light of the present mortality findings, the study is by far the 
largest clinical trial exploring the possibility that good meta- 
bolic control may influence prognosis in diabetic patients. A 
50% exclusion rate before randomization is fairly modest in a 
study involving an initial insulin-glucose infusion followed by 
->3 months of four injections daily. During the time of the study 
angiotensin-converting enzyme inhibitors became recommended 
treatment for patients with compromised left ventricular function 
after a myocardial infarction (44,45); however, the use of these 
agents did not differ between the two groups. 
Mechanisms of action. This study was based on the as- 
sumption that a rapidly achieved and persistent improvement 
in metabolic control should reduce morbidity and mortality in 
diabetic patients with myocardial infarction. It was not de- 
signed to study detailed mechanisms ofaction, and it is difficult 
to separate immediate from long-term effects. Nevertheless, 
some possibilities may be discussed. 
During the acute phase of a myocardial infarction there is a 
dramatic increase of catecholamines in blood and ischemic 
myocardium (46), whereas plasma insulin levels are low 
(47,48). At the same time, cortisol and glucagon levels increase 
(47,49,50). This decreases insulin sensitivity, which contributes 
to impaired glucose utilization. The net effect of these hor- 
monal alterations i  an increased turnover of free fatty acids. 
Patients with diabetes mellitus, particularly those with poor 
metabolic ontrol, are characterized by markedly increased 
plasma levels of free fatty acids and extreme sensitivity to 
catecholamine stimulation (51,52). Normally free fatty acids 
are the primary myocardial substrate, accounting for 60% to 
70% of oxygen consumption (53). In diabetic animals that have 
a reduced glucose utilization, free fatty acids may account for 
90% (54,55). There is no anaerobic pathway for the metabo- 
lism of free fatty acids. Experimental nd clinical observations 
(56,57) suggest hat free fatty acids and their intermediates 
potentiate ischemic injury through several mechanisms such as 
direct oxicity, increased oxygen demand and direct inhibition 
of glucose oxidation. There is a well recognized relation 
between high levels of free fatty acids and complications during 
acute myocardial infarction (58,59). However, free fatty acids 
were not measured in the present study and the possible 
importance of a reduction may only be speculated on. 
As early as 1962 Sodi-Pallares et al. (60) advocated the use 
of insulin-glucose-potassium infusion during acute myocardial 
infarction on the basis that potassium loss was an important 
factor behind cellular esponse to ischemia. This group (61,62) 
demonstrated that insulin-glucose-potassium ncreased intra- 
cellular potassium in the ischemic zone. Subsequent clinical 
studies (21) demonstrated a reduction in the plasma levels of 
free fatty, acids and of the complication rate during acute 
myocardial infarction. In addition to an enhanced segmental 
ejection fraction in the infarcted area, there was evidence of 
improved global eft ventricular function after glucose-insulin- 
potassium infusion (63,64). 
In patients with diabetes mellitus and acute myocardial 
infarction, ejection fraction in the noninfarcted area is lower 
than that in nondiabetic patients (7,65,66). The insulin-glucose 
infusion may have improved untoward metabolic hanges 
during the acute phase of the myocardial infarction, thereby 
preserving myocardium and causing less extensive myocardial 
damage. Some support for this view comes from the finding 
that the enzymatically estimated infarct size tended to be 
larger in the control than in the infusion group. Presumably 
this observation does not fully explain the beneficial results as 
the mortality reduction at the time of hospital discharge was 
still rather small. 
Although many of the recurrent infarcts and a substantial 
proportion of the deaths occur rather early in the postinfarc- 
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tion period, we decided to extend the administration of 
multidose subcutaneous insulin to ->3 months. Intense insulin 
treatment may restore impaired platelet function (25), correct 
the disturbed lipoprotein pattern (67) and decrease plasma 
plasminogen activator inhibitor-1 activity, which is high in 
diabetic patients (27,68). Prolonged insulin treatment may also 
improve the metabolism in the noninfarcted areas, thereby 
reducing the gradual remodeling of the left ventricular myo- 
cardium (18,69). The compliance was good and after the 1-year 
visit 72% of patients in the infusion group were still receiving 
insulin. The extended insulin treatment, with its beneficial 
secondary metabolic effects, is one possible mechanism for the 
reduced long-term mortality in the infusion group. To our 
knowledge, there are no studies showing that good long-term 
metabolic ontrol by means of intense insulin treatment re- 
duces macroangiopathic complications in patients with diabe- 
tes mellitus. However, it was recently shown (70) that intense 
long-term metabolic ontrol reduces microangiopathic compli- 
cations. 
Feasibility and safety. The number of hypoglycemic epi- 
sodes was significantly higher in the infusion group (15%) than 
in the control group (0%). This finding was not unexpected. 
These episodes did not correlate with any increased morbidity 
or mortality and were often discovered as a low blood glucose 
level without any particular symptoms. There was no evidence 
that the insulin-glucose infusion followed by multidose insulin 
caused any harmful effects. A majority of patients in the 
infusion group were treated with multidose insulin during the 
follow-up period without problems. Only 10% had to stop 
insulin therapy because of episodes of hypoglycemia. Feasibil- 
ity and safety aspects, together with descriptions of various 
protocols for insulin-glucose infusion, have been described in 
detail elsewhere (29). 
Conclusions. The present data support he immediate use 
of insulin-glucose infusion followed by rnultidose insulin in 
diabetic patients with acute myocardial infarction. This treat- 
ment seems especially important in those not already receiving 
insulin. The insulin-glucose infusion used in this study did not 
have any untoward effects with the exception of an increased 
number of hypoglycemic episodes; however, these episodes did 
not aggravate signs of ischemia. Future studies hould focus on 
specific pathophysiologic mechanisms behind the beneficial 
effects we have seen. 
Appendix 
The D IGAMI  Study Group*  
Members: Alings~s Hospital, Alingsds: Lars-Olof Olson, MD [5]; 
Arvika-Torsby Hospitals, Arvika: Per Brunmark, MD [6]; Central Hos- 
pitalEskilstuna, Eskilstana: Christina Jarnert, MD, Katarina Ahlin, RN 
[31]; Falu Hospital, Falun: Lars Hagstr6m, MD, Ulla- Britt Engstr6m, 
RN [32]; Giivle-Sandviken Hospitals, Giivle: Rurik L6vmark, MD [5]; 
*The numbers in brackets indicatc number of patients. All cities arc in 
Sweden. 
Sahlgrens Hospital, Gdteborg: Johan Herlitz, MD, Margareta Sj61in, 
RN [71]; Ostra Hospital, Gdteborg: Lennart Welin, MD, Gunnel von 
Hofsten, RN [101]; Ryhov Hospital, J6nk6ping: J6rgen Kuylenstierna, 
MD, Lollo Ekfeldt, RN [37]; K6ping Hospital, K6ping: Peter Nicol, 
MD, Rosamund Eriksson, RN [20]; Karlshamn Hospital, Karlshamn: 
Karim Mohktar, MD, Katarina Ahlin, RN [7]; MalmO General Hospi- 
tal Malm6: Bo Israelsson, MD, Anneli Ivarsson, RN [12]; MOlndal 
Hospital, MOlndah Rune Henning, MD, Anna-Stina Jonsson, RN [11]; 
NykOping Hospital, NykOping: Vibecke Bergman, MD, Sofia Johansson, 
RN [15]; Karolinska Hospital, Stockholm: ,~&e Olsson, MD, Eva 
Olason, RN [51]; Central Hospital, Sk6vde: Peter Smedg~rd, MD, Lis 
StShl, RN [82]; SOdeniilje Hospital, SOdertiilje: Kjell Haglund, MD, 
Louise Andersson, RN [16]; Akademiska Hospital, Uppsala: Gerhard 
Wikstr6m, MD, Marita Adling, RN [59]; V&ter~s Hospital, Viisterg~s: 
Stellan Band, MD, Marie Steneus, RN [7]; Central Hospital, Orebro: 
Erik Schwartz, MD, Helmy Eklund [52]. 
Safety committee: Lars Wallentin, MD, Akademiska Hospital, 
Uppsala; Leif Erhardt, MD, Malm6 General Hospital, Malm6. 
Steering committee: Lars Ryddn, MD (Chairman), Klas Malmberg, 
MD (Principal Investigator), Stockholm; Johan Herlitz, MD, G6teborg; 
Suad Efendic, MD, Stockholm; Anders Waldenstr6m, MD, Uppsala; 
Peter Nicol, MD, K6ping; Lennart Welin, MD, G6teborg; Anders 
Hamsten, MD (Nonvoting), Stockholm; Hans Wedel, PhD, Nordic 
School of Public Health, G6teborg; Anneli Ivarsson, RN, Malta6. 
Publishing committee: Klas Malmberg, MD, Lars Ryd6n, MD, 
Stockholm. 
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